Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a lower incidence of recurrent stroke than aspirin at a dose of 100 mg. Bleeding rates were higher with rivaroxaban.

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 378; číslo 23; s. 2191 - 2201
Hlavní autori:	Hart, Robert G, Sharma, Mukul, Mundl, Hardi, Kasner, Scott E, Bangdiwala, Shrikant I, Berkowitz, Scott D, Swaminathan, Balakumar, Lavados, Pablo, Wang, Yongjun, Wang, Yilong, Davalos, Antonio, Shamalov, Nikolay, Mikulik, Robert, Cunha, Luis, Lindgren, Arne, Arauz, Antonio, Lang, Wilfried, Czlonkowska, Anna, Eckstein, Jens, Gagliardi, Rubens J, Amarenco, Pierre, Ameriso, Sebastian F, Tatlisumak, Turgut, Veltkamp, Roland, Hankey, Graeme J, Toni, Danilo, Bereczki, Daniel, Uchiyama, Shinichiro, Ntaios, George, Yoon, Byung-Woo, Brouns, Raf, Endres, Matthias, Muir, Keith W, Bornstein, Natan, Ozturk, Serefnur, O’Donnell, Martin J, De Vries Basson, Matthys M, Pare, Guillaume, Pater, Calin, Kirsch, Bodo, Sheridan, Patrick, Peters, Gary, Weitz, Jeffrey I, Peacock, W. Frank, Shoamanesh, Ashkan, Benavente, Oscar R, Joyner, Campbell, Themeles, Ellison, Connolly, Stuart J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 07.06.2018
Predmet:	Aged Anticoagulants antithrombotic therapy Aspirin Aspirin - adverse effects Aspirin - therapeutic use Atherosclerosis atrial-fibrillation Bleeding Blood clots Brain Ischemia - prevention & control Cardiac arrhythmia Cardiology and Cardiovascular Disease Clinical Medicine cryptogenic stroke Design Drug dosages efficacy Embolism Embolisms Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female foramen ovale closure General & Internal Medicine Hemorrhage Hemorrhage - chemically induced Hospitals Human health and pathology Humans Internal medicine Intracranial Embolism - drug therapy Ischemia Kaplan-Meier Estimate Kardiologi och kardiovaskulära sjukdomar Klinisk medicin Life Sciences Male Medical and Health Sciences Medical research Medicin och hälsovetenskap Medicine metaanalysis Middle Aged Neurology Neurosciences Patients Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prevention R&D Research & development Research centers Rivaroxaban - adverse effects Rivaroxaban - therapeutic use safety Secondary Prevention - methods Stenosis Stroke Stroke - etiology Stroke - prevention & control Thrombosis trials warfarin Beijing China Canada China
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a lower incidence of recurrent stroke than aspirin at a dose of 100 mg. Bleeding rates were higher with rivaroxaban.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1802686